Tomáš Brtnický

Charles University
Country flagCzech Republic

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Introduction Prehabilitation is an increasingly recognised strategy designed to optimise patients’ physical, nutritional, and psychological status before major surgery. While the benefits of trimodal prehabilitation have been documented, we developed and implemented a quadrimodal model that incorporates occupational therapy as a fourth component. This comprehensive intervention targets frail patients with advanced oncogynecologic disease, a population at high risk for postoperative complications. Material and methods The study recruited 40 patients, 32 of whom successfully completed an intensive 3-week prehabilitation programme. The programme comprised four modules: physiotherapy, nutritional support, psychological support, and occupational therapy. Patients completed 4 days of inpatient care and 3 days of home care per week. The effectiveness of the programme was assessed using a range of methods, including physical tests (6-min walk test, 5 × sit-to-stand test), psychological status questionnaires (perceived stress scale) and nutritional assessment using established questionnaires (MUST and PONS). Results The results demonstrated statistically significant enhancements in physical fitness assessments, a decline in the frailty index, and an augmentation in psychological well-being. Notably, three patients no longer fulfilled the frailty criteria at the conclusion of the programme. Spirometric parameters, including FVC, FEV1, and PEF, exhibited substantial improvement. The nutritional intervention resulted in a reduction in the number of patients at high risk of malnutrition. Additionally, there was a notable improvement in the nutritional parameters. Conclusion This quadrimodal prehabilitation model, integrating occupational therapy, demonstrated effectiveness in preparing frail oncologic patients for radical surgery. The approach not only improved physical and psychological readiness but also allowed for patient stratification into responders and non-responders. Its implementation in clinical practice could enhance patient outcomes and reduce the burden of postoperative recovery.

Year:

2026

Introduction The objective of this study was to assess the impact of the Enhanced Recovery After Surgery (ERAS) programme implementation on treatment costs at a university‐type centre, using the DRG scheme. Materials and Methods Retrospective analysis of patients' data in a group of 604 individuals enroled in the study. We evaluated three groups of patients according to the ERAS clinical protocol (CP): (1) CP oncogynaecology, (2) CP simple hysterectomy, (3) CP laparoscopy. The study aimed to evaluate the impact on the length of stay (LOS), savings in bed‐days, and the reduction in direct treatment costs. Three parameters—antibiotic consumption, blood derivative consumption and laboratory test costs—were chosen to compare direct treatment costs. The statistical significance of the difference in the observed parameters was tested by a two‐sample unpaired t test with unequal variances at the 0.05 significance level. Results We analysed data from 604 patients. In all three groups, the length of stay (LOS) was significantly reduced. The most significant reduction was observed in the CP oncogynaecology group, where the LOS was reduced from 11.1 days to 6.8 days (2022) and 7.6 days (2023) compared to 2019 ( p < 0.05). Furthermore, there was a notable reduction in inpatient bed‐days, which resulted in the capacity being made available to admit additional patients. A statistically significant reduction in direct costs was observed in the group of CP hysterectomy (antibiotic use) and in the CP laparoscopy (laboratory test costs). Conclusions The implementation of the ERAS principles resulted in a number of significant positive economic impacts—reduction in the LOS and a corresponding increase in bed capacity for new patients. Additionally, direct treatment costs, including those related to antibiotic use or laboratory testing were reduced. The Czech Republic's acute healthcare system, like the majority of European healthcare systems, is financed by the DRG system. This flat‐rate payment per patient encourages hospital management to seek cost‐reduction strategies. The results of our study indicate that fast‐track protocols represent a potential viable approach to reducing the cost of treatment while simultaneously meeting the recommendations of evidence‐based medicine.

Year:

2025

NACT-mediated adjuvanticity positively impacts clinically relevant TLS maturation in metastatic HGSOC. A, Representative image of immunofluorescence of CD4, CD8, CD20, CD21, CD23, DC-LAMP, and GZMB staining (immunofluorescence panel 1). Scale bars, 10, 100 and 500 µm. B and C, Distribution of early TLS (eTLS; B ) and mature TLS (mTLS; C ) across pTME and mTME HGSOC tumor samples with/without NACT. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. D, Supervised hierarchical clustering of TLS-relevant gene signature ( CCL2 , CCL3 , CCL4 , CCL5 , CCL8 , CCL18 , CCL19 , CCL21 , CXCL9 , CXCL10 , CXCL11 , and CXCL13 ) across pTME and mTME HGSOC tumor samples with/without NACT. E and F, Overall survival (OS) of 60 ( E ) and 40 chemo-naïve and treated patients with mHGSOC ( F ), respectively (study cohort 1 and 2) based on median stratification of total mTLS. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk and P values are reported. G, Number of mTLS across patients with CALR Lo and CALR Hi mHGSOC with/without NACT as determined by median stratification. Mean and SEM are shown. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. H and I, OS of 60 and 40 patients with chemo-naïve and treated mHGSOC (study cohorts 1 and 2), upon stratification based on median frequency of mTLS and expression of CALR. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using the log-rank test.

Year:

2025

The clinical relevance of combined chemotherapy and immunotherapy in mouse models of TMB Lo and TMB Hi ovarian cancer. A and B, Bar plots showing single-nucleotide variants positions (SNVs) ( A ) and the somatic mutations prevalence (mutations per megabase) ( B ) in ID8 ( n = 3) and Brca1 −/− Trp53 −/− / Myc / Hras SO1 ( n = 3) C57BL/6 syngeneic mouse ovarian cancer cell lines. Mean and SEM are shown. Statistical significance was calculated by multiple t test. P values are indicated. C, Experimental design for the analysis of TLS aggregates development and efficacy of combined chemotherapy and aPD1 and/or aTIM-3 therapy in TMB Lo ID8 and TMB Hi SO1 experimental syngeneic mouse models. D and E, Representative immunostaining for CD4, CD8, CD20, and CD21 ( D ) and a box plot showing density of TLS aggregates within chemo-naïve ( n = 5) and treated TMB Hi SO1 ( n = 9) ovarian tumors ( E ). Scale bars, 100 µm and 2.5 mm. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. F–H, Representative dot plot ( F ) and flow cytometry analyses for percentages of CD62L + CD44 + central memory (CM) and CD62L − CD44 − terminally differentiated CD8 + T cells (TEMRA) ( G ) and TCF1 + PD1 + CD8 + and TIM-3 + PD1 + CD8 + T cells ( H ) in tumor samples of the TMB Hi SO1 experimental model in the presence or absence of carboplatin and taxane chemotherapy (NACT). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. I and J, Overall survival (OS) of TMB Hi SO1 experimental model ( I ) and flow cytometry analyses for percentage of TCF1 + PD1 + CD8 + T cells after NACT, aPD1, aTIM-3 and combined therapy ( J ). Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. K and L, Representative immunostaining for CD4, CD8, CD20, and CD21 ( K ) and a box plot showing density of TLS aggregates within chemo-naïve ( n = 8) and treated TMB Lo ID8 ( n = 8) ( L ) ovarian tumors. Scale bars, 100 µm and 2.5 mm. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. M, Flow cytometry analyses for TCF1 + PD1 + CD8 + and TIM-3 + PD1 + CD8 + T cells in tumor samples of the TMB Lo ID8 experimental model in the presence or absence of carboplatin and taxane chemotherapy (NACT). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. N, Overall survival (OS) of TMB Lo ID8 experimental model after NACT, anti-PD1, and combined therapy. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. P values are indicated. (Panel C created with BioRender.com .)

Year:

2025

NACT-mediated progenitor TCF1 + PD1 + CD8 + T-cell phenotype associates with effector cytotoxic functions within metastatic HGSOC. A–C, Representative dot plot ( A ) and box plot ( B ) showing percentage of TIM-3 + PD1 + CD8 + T cells and GZMB + CD8 + T cells within native pTME and mTME of chemo-naïve and treated HGSOC as determined by flow cytometry. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by the Mann–Whitney test. P values are indicated. C, Marker heatmap dot plots obtained after t-SNE and showing the relative expression of the indicated marker in the different phenotypic clusters within mTME of chemo-naïve and treated HGSOS as determined by flow cytometry. D, Design of experimental and sequencing workflow in 11 patients with HGSOC before and after NACT. scRNAseq was performed on dissociated solid tumor specimens using 10× Genomics Chromium platform. E and F, Uniform manifold approximation and projection (UMAP) plot of all cells ( n = 51,476) passing the quality control, colored by type of therapy ( E ) and cell type ( F ). G and H, TILs projections ( G ) and predicted subtype frequencies ( H ) in biopsies from patients with chemo-naïve and treated HGSOC. CM, central memory; EM, effector memory; MAIT, mucosal-associated invariant T cells; PTEX, progenitor exhausted T cells; TEMRA, terminally exhausted T cells; TEX, exhausted T cells. I and J, Radar plot showing percentage of CD8 + T cells expressing respective T-cell marker ( KLRB1 , TCF7 , CCR7 , IL7R , LMNA , FGFBP2 , XCL1 , CD200 , CRTAM , TOX , PDCD1 , HAVCR2 , and GNLY ; I ) and UMAP showing expression of PDCD1 , HAVCR2 and TCF7 in CD4 + and CD8 + T-cell clusters in chemo-naïve and treated HGSOC samples (study cohort 5; J ), as determined by scRNA-seq. (Panel D created with BioRender.com .)

Year:

2025

Immunomodulation by NACT in metastatic HGSOC. A, Representative images of CALR immunostaining in CALR Lo and CALR Hi patients. Scale bars, 10 and 100 µm. B, CALR expression levels determined by immunostaining and ( C ) ER stress signature level [expression level of DNA damage inducible transcript 3 (DDIT3, best known as CHOP), heat shock protein family A (Hsp70) member 5 (HSPA5, best known as BIP), and heat shock protein 90 beta family member 1 (HSP90B1)] as determined by RNA-seq in pTME and mTME HGSOC with/without NACT. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. D, Supervised hierarchical clustering of gene signatures related to immune populations (orange), immune functions (blue) and immune phenotype (purple) as determined by RNA-seq data from pTME and mTME HGSOC tumor samples with/without NACT. IS, immunosuppression; mDCs, myeloid dendritic cells; NK cells, natural killer cells; TLS, tertiary lymphoid structures. E, Gene expression signature associated with CD8 + T cells, B cells, cytotoxicity, mDCs, TLS, and immunosuppression as determined on RNA-seq data from pTME and mTME HGSOC with/without NACT. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. F, Representative image of CD20/DC-LAMP double immunostaining. Scale bars, 500 and 100 µm. G, Density of CD8 + T cells, CD20 + B cells, and DC-LAMP + cells as determined by immunostaining in pTME and mTME HGSOC samples with/without NACT. Mean and SEM are shown. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. ns, not significant.

Year:

2025

NACT-mediated adjuvanticity positively impacts the density of follicular T cells (T FH ) and in situ activation of intratumoral B cells in mHGSOC. A–C, Representative image ( A ) and box plots showing the density of CD4 + cells ( B ) and CXCR5 + PD1 + FoxP3 − CD4 + T FH cells ( C ) in the pTME and mTME of chemo-naïve and treated HGSOC (study cohort 1 and 2). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by the Mann–Whitney test. P values are indicated. D and E, Dot plot ( D ) and box plot ( E ) showing expression profile of gene signatures of B-cell subtypes, e.g., plasma cells (PC), germinal center (GC), and memory B cells within pTME and mTME HGSOC tumor samples with/without NACT. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. F and G, Representative image ( F ) and density of CD68 + CD163 + TAMs in pTME and mTME of chemo naïve and treated HGSOC ( G ). Mean and SEM are shown. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated.

Year:

2025

Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics and targeted anticancer agents that not only mediate cytotoxic effects but also promote the recruitment of immune effector cells to the HGSOC microenvironment stand out as promising combinatorial partners for ICIs in this oncological indication. Experimental Design: We harnessed a variety of transcriptomic, spatial, and functional assays to characterize the differential impact of neoadjuvant paclitaxel-carboplatin on the immunological configuration of paired primary and metastatic HGSOC biopsies as compared to neoadjuvant chemotherapy (NACT)-naïve HGSOC samples from five independent patient cohorts. Results: We found NACT-driven endoplasmic reticulum stress and calreticulin exposure in metastatic HGSOC lesions culminates with the establishment of a dense immune infiltrate including follicular T cells (T FH cells), a prerequisite for mature tertiary lymphoid structure (TLS) formation. In this context, TLS maturation was associated with an increased intratumoral density of ICI-sensitive TCF1 + PD1 + CD8 + T cells over their ICI-insensitive TIM-3 + PD1 + counterparts. Consistent with this notion, chemotherapy coupled with a PD1-targeting ICI provided a significant survival benefit over either therapeutic approach in syngeneic models of HGSOC bearing high (but not low) tumor mutational burden. Conclusions: Altogether, our findings suggest that NACT promotes TLS formation and maturation in HGSOC lesions, de facto preserving an intratumoral ICI-sensitive T-cell phenotype. These observations emphasize the role of rational design, especially relative to the administration schedule, for clinical trials testing chemotherapy plus ICIs in patients with HGSOC. See related commentary by Bravo Melgar and Laoui, p. 10

Year:

2025

NACT positively increases the ICI-sensitive TCF1 + PD1 + CD8 + T-cell phenotype within metastatic HGSOC. A, Representative image of immunofluorescence of CD68, CD8, PD-L1, FoxP3, TCF1, CD57, PanCK, PD1, CD4, CD20, GZMB, and TIM-3 staining (immunofluorescence panel 2). Scale bars, 2 μm, 10 µm, and 100 µm. B, Violin plot showing the density of CD8 + and PD1 + CD8 + within tumor core and tumor stroma of pTME and mTME of chemo-naïve and treated HGSOC. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. C and D, Representative image ( C ) and box plot showing the density of TCF1 + PD1 + CD8 + T cells and TIM-3 + PD1 + CD8 + and spatial distribution of TCF1 + PD1 + CD8 + T cells within tumor core and stroma in pTME and mTME of chemo-naïve and treated HGSOC ( D ). Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. E, Supervised hierarchical clustering of gene signatures associated with different stages of T-cell differentiation: T-cell stemness (orange), T-cell effector function (blue), T-cell proliferation (green), T-cell phenotype (red) as determined by RNAseq in mTME of chemo-naïve and treated HGSOC. For further details, see Supplementary Fig. S9. F and G, Representative image of digital pathology spatial distribution and violin plot showing the number of cell contacts between PanCK + malignant cells and TCF1 + PD1 + CD8 + T cells and TIM-3 + PD1 + CD8 + within 0 to 30 µm in pTME and mTME of chemo-naïve and treated HGSOC.

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (12)

Josef Pasulka

Czech Academy of Sciences, Institute of Molecular Genetics

CZECH REPUBLIC
View details

Hisashi Tanaka

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Iain McNeish

Imperial College London

UNITED KINGDOM
View details

Petr Hubka

Associate Professor

Charles University

CZECH REPUBLIC
View details

An Coosemans

Katholieke Universiteit Leuven

BELGIUM
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Francis Jacob

Co-Group leader Ovarian Cancer Research

University Hospital Basel

SWITZERLAND
View details

Peter Koliba

-

CZECH REPUBLIC
View details

Lorenzo Galluzzi

-

UNITED STATES
View details

Jan Prochazka

Deputy director, Head of Phenotyping Module

Institute of Molecular Genetics

CZECH REPUBLIC
View details

Pavel Dundr

Charles University

CZECH REPUBLIC
View details

David Cibula

Professor M.D

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details